Profile
Jason Criscione is the founder of Enquyst Technologies Inc., which he founded in 2017 and where he holds the title of Chief Scientific Officer.
He is currently working as a Director at Ansella Therapeutics, Inc.
Jason Criscione active positions
| Companies | Position | Start |
|---|---|---|
Ansella Therapeutics, Inc.
 Ansella Therapeutics, Inc. BiotechnologyHealth Technology Ansella Therapeutics, Inc. develops therapeutic solutions for women's vaginal health. The company is based in Lowell, MA. The company was founded by Mark Goldstone. | Director/Board Member | - |
Enquyst Technologies Inc.
 Enquyst Technologies Inc. Medical SpecialtiesHealth Technology Enquyst Technologies Inc. is a company that is focused on developing next-generation biomanufacturing technology solutions to make life-changing and curative treatments more accessible and affordable for patients worldwide. The company is based in Lowell, MA and was founded by Jason Criscione. The company's patented technology is being applied to solve large unmet needs in the downstream purification of gene therapies, particularly AAV and lentiviral vector-based gene therapies. | Founder | 31/03/2017 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Ansella Therapeutics, Inc.
Ansella Therapeutics, Inc. BiotechnologyHealth Technology Ansella Therapeutics, Inc. develops therapeutic solutions for women's vaginal health. The company is based in Lowell, MA. The company was founded by Mark Goldstone. | Health Technology |
Enquyst Technologies Inc.
Enquyst Technologies Inc. Medical SpecialtiesHealth Technology Enquyst Technologies Inc. is a company that is focused on developing next-generation biomanufacturing technology solutions to make life-changing and curative treatments more accessible and affordable for patients worldwide. The company is based in Lowell, MA and was founded by Jason Criscione. The company's patented technology is being applied to solve large unmet needs in the downstream purification of gene therapies, particularly AAV and lentiviral vector-based gene therapies. | Health Technology |
- Stock Market
- Insiders
- Jason Criscione
